Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Small Cell Lung Carcinoma 19Breast Neoplasms 16Sarcoma 12Lung Neoplasms 9Esophageal Squamous Cell Carcinoma 7Carcinoma, Hepatocellular 7Thyroid Neoplasms 6Stomach Neoplasms 6Nasopharyngeal Carcinoma 6Esophageal Neoplasms 6Ovarian Neoplasms 5NSCLC 5Carcinoma 5Triple Negative Breast Neoplasms 4Pheochromocytoma 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Neoplasms 3Glioma 3Cholangiocarcinoma 3Brain Neoplasms 3Biliary Tract Neoplasms 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Platinum-resistant Ovarian Cancer 2

Interventions

toripalimab 1anlotinib 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Non Small Cell Lung Cancer Recurrent × anlotinib × Clear all
NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Thoracic

Non Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡